Literature DB >> 23604401

Downregulation of aryl hydrocarbon receptor expression decreases gastric cancer cell growth and invasion.

Xiao-Fei Yin1, Jie Chen, Wei Mao, Yu-Hong Wang, Min-Hu Chen.   

Abstract

Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor associated with tumor initiation and progression. AhR expression is significantly increased in gastric cancer tissues and gastric cancer cell lines; however, the relationship between AhR and gastric cancer is still unclear. In the present study, we explored the effects of the inhibition of AhR expression by RNA interference on the biological behavior of gastric cancer cells (MKN45 and SGC7901), and elucidated the specific mechanisms of AhR action in the development of gastric cancer. Results showed that small interfering RNA (siRNA) against AhR effectively inhibited the expression of AhR, and decreased the expression of cytochrome P450 (CYP)1A1 and CYP1B1, which are classic target genes of the AhR pathway. Compared to the negative control group, AhR-siRNA-transfected cells showed decreased cellular growth, delayed G1-S cell cycle progression and increased apoptosis rate. Furthermore, inhibition of AhR expression by siRNA in SGC7901 cells led to decreased cell migratory and invasive ability, accompanied by downregulation of expression and activity of matrix metalloproteinase (MMP)-2 and MMP-9. Our results, therefore, suggest that AhR promotes the growth and invasiveness of gastric cancer cells and AhR may serve as a promising therapeutic target for gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23604401     DOI: 10.3892/or.2013.2410

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

Review 1.  Aryl hydrocarbon receptor ligands in cancer: friend and foe.

Authors:  Iain A Murray; Andrew D Patterson; Gary H Perdew
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

2.  Expression of aryl hydrocarbon receptor in relation to p53 status and clinicopathological parameters in breast cancer.

Authors:  Zheng-Dong Li; Kai Wang; Xin-Wei Yang; Zhi-Gang Zhuang; Jian-Jun Wang; Xiao-Wen Tong
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 3.  Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma.

Authors:  Yunli Zhou; Xun Zhang; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

4.  Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor.

Authors:  Supraja Narasimhan; Elizabeth Stanford Zulick; Olga Novikov; Ashley J Parks; Jennifer J Schlezinger; Zhongyan Wang; Fabrice Laroche; Hui Feng; Francesca Mulas; Stefano Monti; David H Sherr
Journal:  Int J Mol Sci       Date:  2018-05-07       Impact factor: 5.923

5.  Bioinformatics analysis to identify action targets in NCI-N87 gastric cancer cells exposed to quercetin.

Authors:  Yun Zeng; Zhengjie Shen; Wenzhe Gu; Mianhua Wu
Journal:  Pharm Biol       Date:  2018-12       Impact factor: 3.503

6.  Taxifolin suppresses the malignant progression of gastric cancer by regulating the AhR/CYP1A1 signaling pathway.

Authors:  Jiebin Xie; Yueshan Pang; Xiaoting Wu
Journal:  Int J Mol Med       Date:  2021-09-07       Impact factor: 4.101

7.  Differential Expression of Genes Involved in Metabolism and Immune Response in Diffuse and Intestinal Gastric Cancers, a Pilot Ptudy.

Authors:  Martine Perrot-Applanat; Cynthia Pimpie; Sophie Vacher; Ivan Bieche; Marc Pocard; Véronique Baud
Journal:  Biomedicines       Date:  2022-01-23

Review 8.  Fungi, host immune response, and tumorigenesis.

Authors:  Miar Elaskandrany; Rohin Patel; Mintoo Patel; George Miller; Deepak Saxena; Anjana Saxena
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-07-07       Impact factor: 4.871

Review 9.  The Aryl Hydrocarbon Receptor and Tumor Immunity.

Authors:  Ping Xue; Jinrong Fu; Yufeng Zhou
Journal:  Front Immunol       Date:  2018-02-13       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.